Results 31 to 40 of about 182,514 (265)
Determinants of Resistance to Checkpoint Inhibitors [PDF]
International Journal of Molecular Sciences, 2020 The development of immune checkpoint inhibitors (ICIs) has drastically altered the landscape of cancer treatment. Since approval of the first ICI for the treatment of advanced melanoma in 2011, several therapeutic agents have been Food and Drug Administration (FDA)-approved for multiple cancers, and hundreds of clinical trials are currently ongoing ...
Linda Tran, Dan Theodorescu
openaire +2 more sources
Respiratory Medicine Case Reports, 2019 Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically consists of temporary or permanent cessation of the checkpoint inhibitor and several weeks of ...
Camille R. Petri +4 more
doaj +1 more source
Keeping Checkpoint Inhibitors in Check [PDF]
JAMA Network Open, 2019 No ...
Catenacci, Daniel V.T. +2 more
openaire +3 more sources
Cardio-toxicity of checkpoint inhibitors [PDF]
Journal of Thoracic Disease, 2018 Immune checkpoint inhibitors (ICIs) have started revolutionizing the treatment of numerous advanced oncological diseases by restoring immune resistance against cancer cells. ICI-associated cardiac adverse effects are rare, but severe. About 50% of cardiac complications comprise myocarditis with variable clinical presentation and a high rate of fatality.
Oliver J, Müller +2 more
openaire +2 more sources
Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology, 2021 : Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with varying incidence and symptom complexity ...
Zhao, Zhiyi +4 more
openaire +3 more sources
Translational target for checkpoint inhibitors [PDF]
Nature Reviews Immunology, 2018 Eukaryotic translation initiation complex eIF4F is identified as an upstream regulator of PD-L1 expression and is therefore a promising target for immunotherapy.
openaire +2 more sources
Immune Checkpoint Inhibitors in Melanoma [PDF]
Melanoma Management, 2015 The potential to harness the power of the immune system and effectively treat patients with metastatic melanoma is finally being realized with the advent of immune checkpoint inhibitors. These new therapies herald a new era in the treatment of melanoma with the potential to produce very durable responses and possible cure for a subset of patients ...
Adam J, Cooper +2 more
openaire +4 more sources
Frontiers in Oncology, 2023 Immune checkpoint inhibitors cause rare but potentially fatal neuromuscular complications, leading to a concern to use these agents in cancer patients with pre-existing autoimmune or inflammatory neuromuscular diseases.
Ge Xiong +6 more
doaj +1 more source
Lichenoid drug reaction after ipilimumab/nivolumab combination therapy: A case report
SAGE Open Medical Case Reports, 2023 Nivolumab (PD-1 inhibitor) and ipilumumab (CTLA-4 inhibitor) are recently approved checkpoint inhibitors for treatment of non-small cell lung cancer.
Zonía Robenne Moore +5 more
doaj +1 more source
Pharmaceuticals, 2023 Checkpoint inhibitors can be a highly effective antitumor therapy but only to a subset of patients, presumably due to immunotherapy resistance. Fluoxetine was recently revealed to inhibit the NLRP3 inflammasome, and NLRP3 inhibition could serve as a ...
Joseph Magagnoli +6 more
doaj +1 more source